Patient‐reported fatigue refines prognosis in higher‐risk myelodysplastic syndromes (MDS): a MDS‐CAN study Academic Article uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • The incorporation of patient-reported outcomes with traditional disease risk classification was found to strengthen survival prediction in patients with myelodysplastic syndromes (MDS). In the present Canadian MDS registry analysis, we validate a recently reported prognostic model, the Fatigue-International Prognostic Scoring System among higher-risk patients [FA-IPSS(h)], which incorporates patients' reported fatigue, assessed by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life-Core 30 (QLQ-C30), with a threshold of ≥45 points, in higher IPSS score, stratifying them into distinct subgroups with different survival outcomes. We further validated this concept, using the Revised IPSS >3·5 as cut-off for the definition of higher-risk MDS, and patients' reported fatigue according to Edmonton Symptom Self-Assessment Scale (ESAS) Global Fatigue Scale (GFS), a single-item fatigue rating scale, which is easier to deploy. This emphasises the power of self-reported fatigue at refining overall survival predictions in higher-risk MDS and further bolsters the importance of considering patient-related outcomes in global assessments.

authors

  • Amitai, Irina
  • Geddes, Michelle
  • Zhu, Nancy
  • Keating, Mary‐Margaret
  • Sabloff, Mitchell
  • Christou, Grace
  • Leber, Brian
  • Khalaf, Dina
  • Leitch, Heather A
  • St‐Hilaire, Eve
  • Finn, Nicholas
  • Shamy, April
  • Yee, Karen
  • Storring, John
  • Nevill, Thomas
  • Delage, Robert
  • Elemary, Mohamed
  • Banerji, Versha
  • Chodirker, Lisa
  • Mozessohn, Lee
  • Parmentier, Anne
  • Siddiqui, Mohammed
  • Mamedov, Alexandre
  • Zhang, Liying
  • Buckstein, Rena

publication date

  • July 2021